Compare CDIO & SDSTW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CDIO | SDSTW |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | 17 | 10 |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7M | 6.8M |
| IPO Year | N/A | N/A |
| Metric | CDIO | SDSTW |
|---|---|---|
| Price | $1.97 | $0.15 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 57.1K | 7.9K |
| Earning Date | 05-13-2026 | 03-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $171,906.75 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.97 | $0.02 |
| 52 Week High | $7.91 | $0.30 |
| Indicator | CDIO | SDSTW |
|---|---|---|
| Relative Strength Index (RSI) | 51.87 | 54.33 |
| Support Level | $1.72 | $0.10 |
| Resistance Level | $2.13 | $0.16 |
| Average True Range (ATR) | 0.19 | 0.01 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 13.57 | 71.53 |
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.
Stardust Power Inc is developing a lithium refinery at its Facility in Muskogee, Oklahoma, with planned capacity of producing up to 50,000 metric tons per annum of BGLC once fully operational. The company will source lithium brine feedstock from various suppliers and may make investments upstream to secure additional feedstock. The Company seeks to sell its products to electric vehicle (EV) manufacturers as the primary market, with potential applications in other areas such as battery manufacturers, the U.S. military, and original equipment manufacturers (OEMs).